DRF-1042

DRF-1042

D655919-1ml

1ml

10mM in DMSO

充氩,-80℃储存

超低温冰袋运输

DRF-1042 is an orally active derivative of Camptothecin. DRF-1042 acts to inhibit DNA topoisomerase I . DRF-1042 shows good anticancer activity against a panel of human cancer cell lines including multi-agent resistance (MDR) phenotype In Vitro DRF-1042 demonstrates superior lactone stability and good in vitro anticancer activity against a panel of human cancer cell lines including multi-drug resistance (MDR) phenotype. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo In clonogenic assay against murine, canine and human bone marrow cells, DRF-1042 treatment shows less mylosupression that supports the possibility of protracted dose schedule in both experimental and clinical studies. MCE has not independently confirmed the accuracy of these methods. They are for reference only. IC50& Target:DNA topoisomerase I

DRF-1042 是喜树碱的一种口服活性衍生物。DRF-1042 可抑制 DNA 拓扑异构酶 I。DRF-1042 对包括多药耐药性 (MDR) 表型在内的人类癌细胞株具有良好的抗癌活性。

200619-13-2(DMSO)

C22H20N2O6

408.40 g/mol

CCC1(C2=C(COC1=O)C(=O)N3C(C4=CC5=CC=CC=C5N=C4C3=C2)OCCO)O